Call Us: 1.800.873.5297

By

Xarelto® Lawsuit Update: Bayer & Johnson & Johnson Aim to Expand Uses for Xarelto

The Wall Street Journal reports that Johnson & Johnson and Bayer AG recently announced plans to launch clinical trials of Xarelto® against new diseases in order to double the number of indications and widen the market for Xarelto®, which is already poised to exceed $1 billion in sales for 2014. In particular, Yahoo! Finance reports […]

By

FDA Warns of Dangerous Testosterone Risks for Men, NBC News Reports

NBC Nightly News reports that “[t]estosterone treatment is a growing multibillion-dollar business, but it presents the risk of life-threatening blood clots.” In the news segment, the NBC reporter comments: “In 2013, doctors wrote 7.5 million prescriptions for testosterone, up from about 4 million in 2009. While treatment for abnormally low testosterone levels is warranted in […]

By

Low-Testosterone Replacement Therapies Make Cover of Time Magazine: Are They Safe?

The topic of low testosterone (Low-T) replacement therapy drugs will be discussed, along with securing the coveted cover page, in the August 2014 issue of Time Magazine. The magazine will feature an article discussing the $2 Billion testosterone drug industry and detailing the safety concerns centered around Low-T replacement medications. This comes as no surprise […]

By

Xarelto® Surpassing Pradaxa® in Number of Adverse Event Reports, according to Recent ISMP Quarter Watch Report

According to the Institute for Safe Medication Practices’ (ISMP) most recent Quarter Watch Report, Xarelto® (rivaroxaban) has overtaken Pradaxa® (dabigatran) in the number of reported adverse events, including serious bleeding events. The ISMP reports that in 2013, the U.S. Food and Drug Administration (FDA) reported receiving 680 serious adverse event reports from individuals who alleged […]

By

NuvaRing® Lawsuit Update: $100 Million Settlement Will Be Fully Funded by August 2014

Roger Denton and Kristine Kraft, partners at Schlichter, Bogard & Denton, LLP and Co-Lead Counsel in the NuvaRing® Multidistrict Litigation, report that the $100 million NuvaRing® settlement will be fully funded by mid-August 2014. The terms of the NuvaRing® Master Settlement Agreement have been satisfied, which prompted Federal MDL Judge Rodney Sippel, the St. Louis […]

By

FDA Requires Revised Labeling for Testosterone Drugs to Warn of Increased Risk of Blood Clots

On June 20th, the U.S. Food and Drug Administration (FDA) issued a safety warning notifying health care professionals and medical care organizations that it will require manufacturers of approved testosterone products to revise their product labeling to include heightened warnings about the risk of venous blood clots. The previous labeling included the risk of blood […]

By

New Studies Reveal Effects of Testosterone Therapy

Two recent studies have shed some light on the effects that testosterone replacement therapies have on men. In particular, the studies revealed that exercise and obesity significantly impact the success rate of testosterone replacement therapy. Dr. Min Gu Park from Inje University in South Korea conducted a study, which demonstrated that exercise may influence the […]

By

NuvaRing® MDL Lawsuit Update (MDL 1964): NuvaRing® Settlement Opt-In Deadline Extended Until April 9

A $100 Million settlement was approved by United States District Court Judge Rodney W. Sippel in the NuvaRing® Multidistrict Litigation In re: NuvaRing® Products Liability Litigation (MDL No. 1964, Case No. 08-md-1964) on February 7, 2014. The terms of the settlement require that at least 95% of eligible claimants opt into the settlement program. “The […]

By

NuvaRing® MDL Lawsuit Update (MDL 1964): NuvaRing® Settlement Opt-In Deadline Extended Until March 25

On February 7, 2014, United States District Court Judge Rodney W. Sippel approved a $100 Million settlement in the NuvaRing® Multidistrict Litigation In re: NuvaRing® Products Liability Litigation (MDL No. 1964, Case No. 08-md-1964). The terms of the settlement require that at least 95% of eligible claimants opt into the settlement program. “The deadline for […]

By

New Research: Testosterone Drugs Linked to Increased Risk of Blood Clots, Heart Attack and Stroke

The FDA recently announced the launch of an investigation of the cardiovascular risks associated with testosterone therapy. The medical safety alert is to warn men of potential risks and/or side effects associated with testosterone therapy. Studies have shown that, as early as one month and up to the first 90 days after starting testosterone therapy, dangerous […]

000-017   000-080   000-089   000-104   000-105   000-106   070-461   100-101   100-105  , 100-105  , 101   101-400   102-400   1V0-601   1Y0-201   1Z0-051   1Z0-060   1Z0-061   1Z0-144   1z0-434   1Z0-803   1Z0-804   1z0-808   200-101   200-120   200-125  , 200-125  , 200-310   200-355   210-060   210-065   210-260   220-801   220-802   220-901   220-902   2V0-620   2V0-621   2V0-621D   300-070   300-075   300-101   300-115   300-135   3002   300-206   300-208   300-209   300-320   350-001   350-018   350-029   350-030   350-050   350-060   350-080   352-001   400-051   400-101   400-201   500-260   640-692   640-911   640-916   642-732   642-999   700-501   70-177   70-178   70-243   70-246   70-270   70-346   70-347   70-410   70-411   70-412   70-413   70-417   70-461   70-462   70-463   70-480   70-483   70-486   70-487   70-488   70-532   70-533   70-534   70-980   74-678   810-403   9A0-385   9L0-012   9L0-066   ADM-201   AWS-SYSOPS   C_TFIN52_66   c2010-652   c2010-657   CAP   CAS-002   CCA-500   CISM   CISSP   CRISC   EX200   EX300   HP0-S42   ICBB   ICGB   ITILFND   JK0-022   JN0-102   JN0-360   LX0-103   LX0-104   M70-101   MB2-704   MB2-707   MB5-705   MB6-703   N10-006   NS0-157   NSE4   OG0-091   OG0-093   PEGACPBA71V1   PMP   PR000041   SSCP   SY0-401   VCP550  

Legal Disclaimer & Privacy Policy
This web site is designed for general information only. The information presented should not be construed as legal advice and does not form the basis for an attorney/client relationship.

The choice of a lawyer is an important decision and should not be based solely on advertisements.
This web site is not intended to be advertising, and Schlichter Bogard & Denton LLP does not desire to represent anyone desiring representation based upon viewing this web site in a jurisdiction where this web site fails to comply with all laws and ethical rules of that jurisdiction. Materials on this web site may only be reproduced in their entirety (without modification) for the individual reader's personal and/or educational use and must include this notice.

We will not disclose, sell, or rent any of your identifiable personal information to any third party, unless approved by you, or required by law.